- Home
- CISO vs TOVX Comparison
CISO vs TOVX Comparison
Compare CISO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISO | TOVX |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 14.7M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CISO | TOVX |
|---|---|---|
| Price | $0.44 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 387.7K | ★ 1.7M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.31 | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.16 |
| 52 Week High | $1.48 | $0.86 |
Technical Indicators
Market Signals| Indicator | CISO | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 73.09 | 44.87 |
| Support Level | $0.32 | $0.27 |
| Resistance Level | $0.55 | $0.31 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 92.01 | 29.43 |
Price Performance
Historical ComparisonAbout CISO CISO Global Inc.
CISO Global Inc provides cybersecurity compliance and is a software firm composed of trained and seasoned security professionals. The services are used to protect clients' data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in the U.S., Chile, and all other countries. The maximum revenue is generated from the U.S.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.